Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Print
An Overview of Regorafenib in Gastrointestinal Cancers: A Lunch Clinical Research Update
Bringing Regorafenib into Earlier Lines and Stages of Therapy: Where Do We Stand
Saturday, July 2, 2022
14:15 – 14:30
Location: Rooms 133-134; Level 1
Session Speaker(s)
Paul Ross, PhD FRCP
Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom
Learning Objectives:
Regorafenib in 1L HCC: dosage, efficacy, safety
Regorafenib IO combo, rationale for 90mg starting dose
Update on INTRATACE trial